Review

human recombinant cd81 (OriGene)

OriGene is a verified supplier

OriGene manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

OriGene human recombinant cd81
Western blot antibodies used for target verification.

Human Recombinant Cd81, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tp317508/pmc11913887-87-0-4?v=OriGene
Average 93 stars, based on 15 article reviews

human recombinant cd81 - by Bioz Stars, 2026-08

93/100 stars

Images

1) Product Images from "Toward Identification of Markers for Brain‐Derived Extracellular Vesicles in Cerebrospinal Fluid: A Large‐Scale, Unbiased Analysis Using Proximity Extension Assays"

Article Title: Toward Identification of Markers for Brain‐Derived Extracellular Vesicles in Cerebrospinal Fluid: A Large‐Scale, Unbiased Analysis Using Proximity Extension Assays

Journal: Journal of Extracellular Vesicles

doi: 10.1002/jev2.70052

Figure Legend Snippet: Western blot antibodies used for target verification.

Techniques Used: Western Blot

$CSF SEC fractionation as a measure of EV association. (a) Quantification of CSF fractions using a Simoa assay for CD81. Four individual healthy CSF samples were fractionated using SEC, and each fraction was analysed by Simoa. A Mann–Whitney U test performed comparing fractions 9 and 10 with fractions 7, 11, 12 and 13 in all samples combined showed fractions 9 and 10 are significantly greater than fractions 7, 11, 12 and 13 ( p < 0.0005). (b) Quantification of CSF fractions using the Olink assay for CD63. Four individual healthy samples were fractionated using SEC, and each fraction was analysed by the Olink HT panel. The Mann–Whitney U test performed comparing fractions 9 and 10 with fractions 7, 11, 12 and 13 in all samples combined showed fractions 9 and 10 are significantly greater than fractions 7, 11, 12 and 13 ( p < 0.0005). (c) Heat maps showing normalized NPX values for each SEC fraction for four representative previously published EV contaminants and four EV‐associated proteins in the Olink panel. Of note, the EV contaminant proteins F2, C3, FN1 and SERPINF1 (PEDF) all have increasingly high NPX values predominantly in the late free protein fractions. EV‐associated proteins ANXA2, ANXA4, ANXA5 and VTA1 show EV‐associated fractionation patterns with high NPX values in fractions 9 and 10. Anxa5 and VTA1 also show NPX signals in later fractions 14 and 15, suggesting possibly soluble protein isoforms for these proteins. (d) Percentage of Deep TMHMM predicted transmembrane, internal, and external targets quantified by Olink as having an EV fractionation pattern in CSF. CSF, cerebrospinal fluid; NPX, normalized protein expression; PEDF, pigment epithelium‐derived factor; SEC, size exclusion chromatography.$
Figure Legend Snippet: CSF SEC fractionation as a measure of EV association. (a) Quantification of CSF fractions using a Simoa assay for CD81. Four individual healthy CSF samples were fractionated using SEC, and each fraction was analysed by Simoa. A Mann–Whitney U test performed comparing fractions 9 and 10 with fractions 7, 11, 12 and 13 in all samples combined showed fractions 9 and 10 are significantly greater than fractions 7, 11, 12 and 13 ( p < 0.0005). (b) Quantification of CSF fractions using the Olink assay for CD63. Four individual healthy samples were fractionated using SEC, and each fraction was analysed by the Olink HT panel. The Mann–Whitney U test performed comparing fractions 9 and 10 with fractions 7, 11, 12 and 13 in all samples combined showed fractions 9 and 10 are significantly greater than fractions 7, 11, 12 and 13 ( p < 0.0005). (c) Heat maps showing normalized NPX values for each SEC fraction for four representative previously published EV contaminants and four EV‐associated proteins in the Olink panel. Of note, the EV contaminant proteins F2, C3, FN1 and SERPINF1 (PEDF) all have increasingly high NPX values predominantly in the late free protein fractions. EV‐associated proteins ANXA2, ANXA4, ANXA5 and VTA1 show EV‐associated fractionation patterns with high NPX values in fractions 9 and 10. Anxa5 and VTA1 also show NPX signals in later fractions 14 and 15, suggesting possibly soluble protein isoforms for these proteins. (d) Percentage of Deep TMHMM predicted transmembrane, internal, and external targets quantified by Olink as having an EV fractionation pattern in CSF. CSF, cerebrospinal fluid; NPX, normalized protein expression; PEDF, pigment epithelium‐derived factor; SEC, size exclusion chromatography.

Techniques Used: Fractionation, MANN-WHITNEY, Expressing, Derivative Assay, Size-exclusion Chromatography

Image Search Results

Journal: Journal of Extracellular Vesicles

Article Title: Toward Identification of Markers for Brain‐Derived Extracellular Vesicles in Cerebrospinal Fluid: A Large‐Scale, Unbiased Analysis Using Proximity Extension Assays

doi: 10.1002/jev2.70052

Figure Lengend Snippet: Western blot antibodies used for target verification.

Article Snippet: Human recombinant CD81 from Origene (TP317508) was used in the calibration curve.

Techniques: Western Blot

Journal: Journal of Extracellular Vesicles

Article Title: Toward Identification of Markers for Brain‐Derived Extracellular Vesicles in Cerebrospinal Fluid: A Large‐Scale, Unbiased Analysis Using Proximity Extension Assays

doi: 10.1002/jev2.70052

Figure Lengend Snippet: CSF SEC fractionation as a measure of EV association. (a) Quantification of CSF fractions using a Simoa assay for CD81. Four individual healthy CSF samples were fractionated using SEC, and each fraction was analysed by Simoa. A Mann–Whitney U test performed comparing fractions 9 and 10 with fractions 7, 11, 12 and 13 in all samples combined showed fractions 9 and 10 are significantly greater than fractions 7, 11, 12 and 13 ( p < 0.0005). (b) Quantification of CSF fractions using the Olink assay for CD63. Four individual healthy samples were fractionated using SEC, and each fraction was analysed by the Olink HT panel. The Mann–Whitney U test performed comparing fractions 9 and 10 with fractions 7, 11, 12 and 13 in all samples combined showed fractions 9 and 10 are significantly greater than fractions 7, 11, 12 and 13 ( p < 0.0005). (c) Heat maps showing normalized NPX values for each SEC fraction for four representative previously published EV contaminants and four EV‐associated proteins in the Olink panel. Of note, the EV contaminant proteins F2, C3, FN1 and SERPINF1 (PEDF) all have increasingly high NPX values predominantly in the late free protein fractions. EV‐associated proteins ANXA2, ANXA4, ANXA5 and VTA1 show EV‐associated fractionation patterns with high NPX values in fractions 9 and 10. Anxa5 and VTA1 also show NPX signals in later fractions 14 and 15, suggesting possibly soluble protein isoforms for these proteins. (d) Percentage of Deep TMHMM predicted transmembrane, internal, and external targets quantified by Olink as having an EV fractionation pattern in CSF. CSF, cerebrospinal fluid; NPX, normalized protein expression; PEDF, pigment epithelium‐derived factor; SEC, size exclusion chromatography.

Article Snippet: Human recombinant CD81 from Origene (TP317508) was used in the calibration curve.

Techniques: Fractionation, MANN-WHITNEY, Expressing, Derivative Assay, Size-exclusion Chromatography

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet:

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Recombinant, Purification, Chromatography

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet:

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Enzyme-linked Immunosorbent Assay, Recombinant, Purification, Chromatography

$( A ) Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured by Simoa after SEC of 1 ml plasma in each fraction using either Sepharose CL-2B, Sepharose CL-4B, or Sepharose CL-6B resin. ( B ) Extracellular vesicle (EV) yield is calculated in fractions 7–10 for Sepharose CL-2B, Sepharose CL-4B, or Sepharose CL-6B by averaging the ratios of CD9, CD63, and CD81. ( C ) Purity of EVs with respect to lipoproteins or free proteins is calculated by dividing relative EV yield (the average of the ratios of CD9, CD63, and CD81) by levels of ApoB-100 (top) or albumin (bottom). Error bars represent the standard deviation of four columns measured on different days with two technical replicates each. Figure 2—source data 1. Simoa data (protein concentrations) for fractions of SEC columns with different resins. Figure 2—source data 2. Simoa data (protein concentrations) for SEC column with different number of washes.$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: ( A ) Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured by Simoa after SEC of 1 ml plasma in each fraction using either Sepharose CL-2B, Sepharose CL-4B, or Sepharose CL-6B resin. ( B ) Extracellular vesicle (EV) yield is calculated in fractions 7–10 for Sepharose CL-2B, Sepharose CL-4B, or Sepharose CL-6B by averaging the ratios of CD9, CD63, and CD81. ( C ) Purity of EVs with respect to lipoproteins or free proteins is calculated by dividing relative EV yield (the average of the ratios of CD9, CD63, and CD81) by levels of ApoB-100 (top) or albumin (bottom). Error bars represent the standard deviation of four columns measured on different days with two technical replicates each. Figure 2—source data 1. Simoa data (protein concentrations) for fractions of SEC columns with different resins. Figure 2—source data 2. Simoa data (protein concentrations) for SEC column with different number of washes.

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Clinical Proteomics, Standard Deviation

$Levels of CD9, CD63, CD81, albumin, and ApoB-100 were measured by Simoa in individual 1 ml fractions (collected from the top) after density gradient centrifugation of plasma using an iodixanol gradient. Error bars represent the standard deviation of two replicates of each measurement. Figure 3—source data 1. Simoa data (protein concentrations) for different density gradient centrifugation fractions.$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: Levels of CD9, CD63, CD81, albumin, and ApoB-100 were measured by Simoa in individual 1 ml fractions (collected from the top) after density gradient centrifugation of plasma using an iodixanol gradient. Error bars represent the standard deviation of two replicates of each measurement. Figure 3—source data 1. Simoa data (protein concentrations) for different density gradient centrifugation fractions.

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Gradient Centrifugation, Clinical Proteomics, Standard Deviation

$Levels of CD9, CD63, CD81, ApoB-100 albumin were measured (in duplicate and then averaged) by Simoa to compare extracellular vesicle (EV) isolation from 1 ml plasma using density gradient (DG) centrifugation, SEC, or density gradient centrifugation followed by size exclusion chromatography (DG-SEC). For the DG and DG-SEC condition, fraction 10 was analyzed. Simoa measurements were used to quantify relative EV recovery ( A ), EV/ApoB-100 ratio ( B ), and EV/albumin ratio ( C ).$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: Levels of CD9, CD63, CD81, ApoB-100 albumin were measured (in duplicate and then averaged) by Simoa to compare extracellular vesicle (EV) isolation from 1 ml plasma using density gradient (DG) centrifugation, SEC, or density gradient centrifugation followed by size exclusion chromatography (DG-SEC). For the DG and DG-SEC condition, fraction 10 was analyzed. Simoa measurements were used to quantify relative EV recovery ( A ), EV/ApoB-100 ratio ( B ), and EV/albumin ratio ( C ).

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Isolation, Clinical Proteomics, Centrifugation, Gradient Centrifugation, Size-exclusion Chromatography

( A ) Levels of CD9, CD63, CD81, and albumin were measured by Simoa after EV isolation from 1 ml plasma with size exclusion chromatography (SEC) using 0, 1, 2, or 3 in-column 10 ml PBS washes. Error bars represent the standard deviation from two technical replicates. ( B ) Percent recovery of EVs using average of ratios of CD9, CD63, and CD81 in SEC isolation relative to plasma.

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: ( A ) Levels of CD9, CD63, CD81, and albumin were measured by Simoa after EV isolation from 1 ml plasma with size exclusion chromatography (SEC) using 0, 1, 2, or 3 in-column 10 ml PBS washes. Error bars represent the standard deviation from two technical replicates. ( B ) Percent recovery of EVs using average of ratios of CD9, CD63, and CD81 in SEC isolation relative to plasma.

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Isolation, Clinical Proteomics, Size-exclusion Chromatography, Standard Deviation

$( A ) Schematic of the columns being compared: size exclusion chromatography (SEC) column comprised of 10 ml Sepharose CL-6B, dual-mode chromatography (DMC) columns comprised of 10 ml Sepharose CL-6B SEC resin atop 2 ml Fractogel cation exchange resin, Tri-Mode Chromatography (TMC) columns comprised of 10 ml Sepharose CL-6B SEC resin atop 2 ml 2:1 ratio of 2 ml Fractogel cation exchange resin to Capto Core 700 multimodal chromatography resin. ( B ) Electron microscopy of EVs isolated from plasma using SEC (left), DMC (middle), or TMC (right) columns. EVs indicated with red arrows (among background of lipoproteins). ( C ) EV recovery is calculated for EV isolation from plasma for SEC (fractions 7–10), DMC (fractions 9–12), or TMC (fractions 9–12). Simoa measurements in the designated fractions for CD9, CD63, and CD81 are taken as a ratio relative to measurements of these proteins from diluted plasma and these three ratios are then averaged to calculate recovery. ( D ) Purity of EVs with respect to free proteins is determined by dividing relative EV yield (the average of the ratios of CD9, CD63, and CD81) by relative levels of albumin in each condition. ( E ) Purity of EVs with respect to lipoproteins is determined by dividing relative EV yield (the average of the ratios of CD9, CD63, and CD81) by relative levels of ApoB-100 in each condition. Error bars represent the standard deviation of four column measured on different days with two technical replicates each. Figure 4—source data 1. Simoa data (protein concentrations) for TMC columns with different ratios of resins in the bottom layer. Figure 4—source data 2. Simoa data (protein concentrations) for different fractions of SEC and DMC columns. Figure 4—source data 3. Simoa data (protein concentrations) comparing SEC (fractions 7-10), DMC and TMC columns (fractions 9-12).$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: ( A ) Schematic of the columns being compared: size exclusion chromatography (SEC) column comprised of 10 ml Sepharose CL-6B, dual-mode chromatography (DMC) columns comprised of 10 ml Sepharose CL-6B SEC resin atop 2 ml Fractogel cation exchange resin, Tri-Mode Chromatography (TMC) columns comprised of 10 ml Sepharose CL-6B SEC resin atop 2 ml 2:1 ratio of 2 ml Fractogel cation exchange resin to Capto Core 700 multimodal chromatography resin. ( B ) Electron microscopy of EVs isolated from plasma using SEC (left), DMC (middle), or TMC (right) columns. EVs indicated with red arrows (among background of lipoproteins). ( C ) EV recovery is calculated for EV isolation from plasma for SEC (fractions 7–10), DMC (fractions 9–12), or TMC (fractions 9–12). Simoa measurements in the designated fractions for CD9, CD63, and CD81 are taken as a ratio relative to measurements of these proteins from diluted plasma and these three ratios are then averaged to calculate recovery. ( D ) Purity of EVs with respect to free proteins is determined by dividing relative EV yield (the average of the ratios of CD9, CD63, and CD81) by relative levels of albumin in each condition. ( E ) Purity of EVs with respect to lipoproteins is determined by dividing relative EV yield (the average of the ratios of CD9, CD63, and CD81) by relative levels of ApoB-100 in each condition. Error bars represent the standard deviation of four column measured on different days with two technical replicates each. Figure 4—source data 1. Simoa data (protein concentrations) for TMC columns with different ratios of resins in the bottom layer. Figure 4—source data 2. Simoa data (protein concentrations) for different fractions of SEC and DMC columns. Figure 4—source data 3. Simoa data (protein concentrations) comparing SEC (fractions 7-10), DMC and TMC columns (fractions 9-12).

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Size-exclusion Chromatography, Chromatography, Electron Microscopy, Isolation, Clinical Proteomics, Standard Deviation

$Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured (in duplicate and then averaged) by Simoa in extracellular vesicle (EV) samples isolated from 1 ml plasma to compare TMC columns with different volumes and ratios of Fractogel cation exchange resin to Capto Core 700 resin. All conditions describe the bottom layer under a 10 ml Sepharose CL-6B top layer. The 1, 2, or 4 ml volume of the bottom later indicates the volume of the solid resin mixture of Fractogel cation exchange resin and Capto Core 700 resin. The following fractions were collected for each: 8–11 for 1 ml bottom layer, 9–12 for 2 ml bottom layer, and 11–14 for 4 ml bottom layer.$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured (in duplicate and then averaged) by Simoa in extracellular vesicle (EV) samples isolated from 1 ml plasma to compare TMC columns with different volumes and ratios of Fractogel cation exchange resin to Capto Core 700 resin. All conditions describe the bottom layer under a 10 ml Sepharose CL-6B top layer. The 1, 2, or 4 ml volume of the bottom later indicates the volume of the solid resin mixture of Fractogel cation exchange resin and Capto Core 700 resin. The following fractions were collected for each: 8–11 for 1 ml bottom layer, 9–12 for 2 ml bottom layer, and 11–14 for 4 ml bottom layer.

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Isolation, Clinical Proteomics

$Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured by Simoa in fractions 7–10 for SEC with 10 ml Sepharose CL-6B column and fractions 7–14 for DMC using a column with 2 ml Fractogel cation exchange bottom layer and 10 ml Sepharose CL-6B top layer. Error bars represent the standard deviation from two technical replicates.$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured by Simoa in fractions 7–10 for SEC with 10 ml Sepharose CL-6B column and fractions 7–14 for DMC using a column with 2 ml Fractogel cation exchange bottom layer and 10 ml Sepharose CL-6B top layer. Error bars represent the standard deviation from two technical replicates.

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Standard Deviation

$Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured by Simoa in extracellular vesicle (EV) samples isolated from 1 ml plasma using SEC (fractions 7–10), DMC (fractions 9–12), or TMC columns (fractions 9–12). Error bars represent the standard deviation of four column measured on different days with two technical replicates each.$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: Levels of CD9, CD63, CD81, ApoB-100, and albumin were measured by Simoa in extracellular vesicle (EV) samples isolated from 1 ml plasma using SEC (fractions 7–10), DMC (fractions 9–12), or TMC columns (fractions 9–12). Error bars represent the standard deviation of four column measured on different days with two technical replicates each.

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Isolation, Clinical Proteomics, Standard Deviation

$( A ) CAD image of semi-automated SEC stand designed to hold eight columns at once with sliding collection tube holder that allows liquid to drip either into 2 ml collection tubes, or to waste. ( B ) Photograph of stand connected to a Tecan Cavro syringe pump controlled by a Raspberry Pi. ( C ) Simoa comparison of CD9, CD63, CD81, ApoB-100, and albumin when SEC was performed on 16 samples of 1 ml plasma using either manual SEC (8 samples) or SEC on the automated device (8 samples). Each point is the average of two Simoa measurements (technical replicates). Figure 5—source data 1. Simoa data (protein concentrations) comparing manual and automated SEC EV isolation (fractions 7-10).$

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet: ( A ) CAD image of semi-automated SEC stand designed to hold eight columns at once with sliding collection tube holder that allows liquid to drip either into 2 ml collection tubes, or to waste. ( B ) Photograph of stand connected to a Tecan Cavro syringe pump controlled by a Raspberry Pi. ( C ) Simoa comparison of CD9, CD63, CD81, ApoB-100, and albumin when SEC was performed on 16 samples of 1 ml plasma using either manual SEC (8 samples) or SEC on the automated device (8 samples). Each point is the average of two Simoa measurements (technical replicates). Figure 5—source data 1. Simoa data (protein concentrations) comparing manual and automated SEC EV isolation (fractions 7-10).

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Comparison, Clinical Proteomics, Isolation

Journal: eLife

Article Title: Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins

doi: 10.7554/eLife.86394

Figure Lengend Snippet:

Article Snippet: Peptide, recombinant protein , CD81 , Origene , Cat# TP317508 , .

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Recombinant, Purification, Chromatography

$a, Schematic overview of an SEC experiment for evaluating whether L1CAM is associated with EVs. b, L1CAM concentration in SEC fractions after fractionation of EVs derived from iNGN cells expressing L1CAM (top) and after fractionation of soluble recombinant L1CAM protein (bottom). Data represent a single experiment in which two technical replicates were averaged. This experiment was conducted once. c, Simoa quantification of CD9, CD63, CD81, albumin and L1CAM levels in Sepharose 6B 10-ml SEC fractions of CSF (top) and plasma (bottom). Data represent a single experiment in which a single pooled sample was used, and two technical replicates were averaged. This experiment was conducted six times with biofluid samples from different sources, and the results were consistent.$

Journal: Nature methods

Article Title: L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma

doi: 10.1038/s41592-021-01174-8

Figure Lengend Snippet: a, Schematic overview of an SEC experiment for evaluating whether L1CAM is associated with EVs. b, L1CAM concentration in SEC fractions after fractionation of EVs derived from iNGN cells expressing L1CAM (top) and after fractionation of soluble recombinant L1CAM protein (bottom). Data represent a single experiment in which two technical replicates were averaged. This experiment was conducted once. c, Simoa quantification of CD9, CD63, CD81, albumin and L1CAM levels in Sepharose 6B 10-ml SEC fractions of CSF (top) and plasma (bottom). Data represent a single experiment in which a single pooled sample was used, and two technical replicates were averaged. This experiment was conducted six times with biofluid samples from different sources, and the results were consistent.

Article Snippet: Reagents were cross-tested for signal against the following recombinant proteins for CD9, CD63, CD81, L1CAM and albumin: ab152262 (Abcam), TP301733 (OriGene), CD81 OriGene TP317508 (OriGene), TP311601 (OriGene) and ab201876 (Abcam) on a Simoa HD-X Analyzer (Quanterix).

Techniques: Concentration Assay, Fractionation, Derivative Assay, Expressing, Recombinant

$a, Simoa quantification of CD9, CD63, CD81, albumin and L1CAM levels in DGC fractions of CSF (left) and plasma (right). The density of fractions 1–11 were as follows in units of g ml−1: 1.012, 1.028, 1.045, 1.056, 1.065, 1.076, 1.097, 1.113, 1.138, 1.193 and 1.219. Data represent a single experiment in which a single pooled sample was used, and two technical replicates were averaged. This experiment was conducted twice with similar results. b, Schematic representation of putative L1CAM isoforms present in the human body. c, Western blotting of L1CAM immunocaptured in CSF and plasma using an antibody to the external domain of L1CAM (clone EPR23241-224). Staining was performed with one antibody to an external domain (clone UJ127) or one antibody to an internal domain (clone 2C2). This experiment was conducted twice with similar results.$

Journal: Nature methods

Article Title: L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma

doi: 10.1038/s41592-021-01174-8

Figure Lengend Snippet: a, Simoa quantification of CD9, CD63, CD81, albumin and L1CAM levels in DGC fractions of CSF (left) and plasma (right). The density of fractions 1–11 were as follows in units of g ml−1: 1.012, 1.028, 1.045, 1.056, 1.065, 1.076, 1.097, 1.113, 1.138, 1.193 and 1.219. Data represent a single experiment in which a single pooled sample was used, and two technical replicates were averaged. This experiment was conducted twice with similar results. b, Schematic representation of putative L1CAM isoforms present in the human body. c, Western blotting of L1CAM immunocaptured in CSF and plasma using an antibody to the external domain of L1CAM (clone EPR23241-224). Staining was performed with one antibody to an external domain (clone UJ127) or one antibody to an internal domain (clone 2C2). This experiment was conducted twice with similar results.

Techniques: Western Blot, Staining

Review

Structured Review

Images

1) Product Images from "Toward Identification of Markers for Brain‐Derived Extracellular Vesicles in Cerebrospinal Fluid: A Large‐Scale, Unbiased Analysis Using Proximity Extension Assays"

Similar Products

Image Search Results